SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis
Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for
